1. 1) WHO. Pharmacovigilance. [http://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/ (accessed 2015-3-20)]
2. 11) Osaki M, Tatsuki K, Hashikawa T, et al. Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women. Osteoporos Int 2012; 23(2): 695-703.
3. 19) The International Society of Pharmacoepidemiology. Guidelines for Good Pharmacoepidemiology Practices (GPP). Revision 2. [http://pharmacoepi.org/resources/guidelines_08027.cfm (accessed 2015-3-20)]
4. 24) European Medicines Agency. Guideline on good pharmacovigilance practices (GVP), Module VI-Management and reporting of adverse reactions to medicinal products. 2 July 2012. [http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129135.pdf (accessed 2015-3-20)]
5. 29) Tanaka K, Morita Y, Kawabe E, Kubota K. Drug use investigation (DUI) and prescription-event monitoring in Japan (J-PEM). Pharmacoepidemiol Drug Saf 2001; 10(7): 653-8.